TABLE 1.
Pharmacokinetic parameters for indinavir and efavirenz by study arm
| Regimena | Cmax (nM) | Cmin (nM) | CL/F (liters/h) | Vss/F (liters) | t1/2 (h) |
|---|---|---|---|---|---|
| Indinavir | |||||
| 1,000 mg q8h (arm I) | 13,040 (6,184-22,260)b | 168.2 (81.9-257.0) | 98.4 (38.7-207.0) | 103.4 (28.4-135.1) | 2.3 (1.7-2.6) |
| 1,000 mg q8h and abacavir (arm II) | 9,253 (4,082-11,220) | 110.40 (68.8-308.7) | 103.0 (62.0-231.1) | 108.8 (71.0-179.0) | 1.9 (1.4-3.4) |
| 1,200 mg q12h (arm III) | 20,000 (8,655-22,390) | 55.0 (10.2-93.5) | 73.9 (51.8-104.4) | 29.1 (25.6-136.4) | 1.9 (1.4-2.4) |
| 1,200 mg q12h and abacavir (arm IV) | 13,695 (8,305-17,060) | 97.7 (73.6-144.5) | 71.3 (60.7-96.9) | 48.3 (35.0-109.2) | 2.3 (1.9-2.9) |
| Efavirenz | |||||
| 600 mg q24h (arm I) | 10,723.6 (7,513.1-12,439.4) | 5,630.4 (3,408.4-6,181.6) | 10.8 (8.6-19.9) | 363.7 (272.2-864.4) | 23.6 (20.2-29.4) |
| 600 mg q24h and abacavir (arm II) | 7,826.25 (5,783.5-10,791.2) | 3,016.4 (2,462.3-5,623.4) | 16.8 (11.2-20.0) | 554.5 (407.6-688.7) | 21.8 (19.4-31.6) |
| 300 mg q12h (arm III) | 8,381.72 (4,994.48-11,126.32) | 3,922.95 (2,976.7-6,643.6) | 13.3 (9.9-19.5) | 397.0 (283.5-549.1) | 20.9 (10.1-37.6) |
| 300 mg q12h and abacavir (arm IV) | 8,316.98 (6,587.03-10,239.15) | 4,909.7 (3,389.9-7,258.7) | 12.4 (9.2-15.8) | 478.1 (227.9-602.9) | 18.3 (12.6-39.8) |
a
The numbers of subjects included in indinavir arms I, II, III and IV were 5, 9, 7, and 14, respectively, and the numbers of subjects included in efavirenz arms I, II, III, and IV were 4, 8, 6, and 7, respectively.
b
The values are medians (IRs).